Korea MFDS Health Functional Food: HFF, Functional Ingredients and Lifecycle Readiness
Korea regulates supplements as Health Functional Food (HFF, 건강기능식품) under the Health Functional Foods Act administered by the Ministry of Food and Drug Safety (MFDS, formerly KFDA).
In Short
- Health Functional Food (HFF) is defined under Article 3 of the Health Functional Foods Act as food manufactured (including processing) using functional ingredients…
- Generic HFF uses functional ingredients from the MFDS-published Functional Ingredient List (approximately 90+ generic ingredients including vitamins, minerals,…
- Individually-Approved HFF (개별인정형) is the pathway for novel functional ingredients not on the Generic Functional Ingredient List, requiring full MFDS scientific…
HFF status is mandatory for any product marketed with health-function claims. The regulatory framework operates on two pathways: Generic HFF using ingredients on the MFDS-published Functional Ingredient List, and Individually-Approved HFF for novel functional ingredients requiring full MFDS scientific evidence review. HFF facilities must hold HFF GMP certification. Korea's supplement market is one of the most developed in Asia by per-capita consumption and operates with distinctive regulatory rigor and consumer-facing labelling discipline. This guide covers the HFF framework, functional ingredient pathways, GMP, labelling and lifecycle controls.
The HFF framework — what is and is not a Health Functional Food
Health Functional Food (HFF) is defined under Article 3 of the Health Functional Foods Act as food manufactured (including processing) using functional ingredients or components that maintain physiological function in the human body. The HFF classification is required for any product marketed with health-function claims in Korea — products without HFF status cannot claim physiological function regardless of formulation or evidence.
More on the HFF framework — what is and is not a Health Functional Food
Functional ingredients are categorised by MFDS into three function types: Function I (nutrient function, structural maintenance, e.g. vitamin D for bone), Function II (reduce risk of disease — narrow set with strong evidence), and the broader physiological function category covering immune support, antioxidation, blood lipid, blood sugar, cognitive, joint, eye, gastrointestinal, fatigue, sleep, weight, skin and other physiological functions with MFDS-approved evidence. The framework distinguishes HFF (regulated) from general food (unregulated for function claims) and from pharmaceutical/biopharmaceutical drugs (regulated under separate pharmaceutical framework). The supplement market segment in Korea is dominated by HFF — domestic and imported.
Generic HFF and the Functional Ingredient List
Generic HFF uses functional ingredients from the MFDS-published Functional Ingredient List (approximately 90+ generic ingredients including vitamins, minerals, omega-3 fatty acids, probiotics, dietary fibre, ginseng, red ginseng, plant sterol esters, glucosamine, coenzyme Q10, lutein, EGCG and others) with MFDS-specified daily dose ranges and function claims. Generic HFF applications are streamlined — typical 90-day MFDS review for manufacturer registration of a product formulated within the generic scope.
More on generic HFF and the Functional Ingredient List
Imported generic HFF products require Korean importer registration with MFDS, product registration per imported SKU, and overseas manufacturer GMP equivalence verification. The Generic pathway is the dominant entry mode for vitamin, mineral, omega-3, probiotic and common-functional supplements. Each generic ingredient has a published monograph with daily intake range (e.g. ginseng 0.6-3 g/day, red ginseng 1.7-7.5 g/day, omega-3 EPA+DHA 0.5-2 g/day, probiotics 0.1-10 billion CFU/day depending on strain), function-claim wording (e.g. for fatigue recovery, for cognitive function, for immune support), conditions of use, manufacturing requirements and standard analytical methods.
Individually-Approved HFF for Novel Ingredients
Individually-Approved HFF (개별인정형) is the pathway for novel functional ingredients not on the Generic Functional Ingredient List, requiring full MFDS scientific evidence review of safety, function, manufacturing standardisation and analytical methods. The dossier covers comprehensive safety evaluation (toxicology, sub-chronic and chronic toxicity, reproductive and developmental toxicity, genotoxicity), function evaluation (in vitro mechanism, in vivo animal models, human clinical trials for the claimed physiological function), manufacturing process and quality control (raw material specification, manufacturing process, finished functional ingredient specification, stability), and standard analytical method for routine release and surveillance.
More on individually-Approved HFF for Novel Ingredients
Review timeline is typically 6-18 months. Individually-Approved status is granted to the specific applicant (commercial protection mechanism) with the approved functional ingredient and claim — competitors must obtain independent approval or wait for the approved ingredient to migrate to the Generic List (typically after multiple independent approvals and broad commercialisation). The Individually-Approved pathway is the route for differentiated Korean brand-owner R&D programmes and for international brands with strong novel-ingredient evidence packages.
HFF GMP and the manufacturing facility framework
HFF facilities — domestic and overseas — must hold HFF GMP certification under the Health Functional Foods Act and the MFDS HFF GMP standard. The standard is aligned with international pharmaceutical and food GMP frameworks but with HFF-specific elements covering functional ingredient handling, label and claim controls, traceability per HFF lot and adverse reaction monitoring.
More on hFF GMP and the manufacturing facility framework
Domestic Korean HFF manufacturers hold direct MFDS HFF GMP certification following on-site inspection. Overseas manufacturers supplying imported HFF require either MFDS overseas-manufacturer registration with documented GMP equivalent to MFDS HFF GMP (typically supported by FDA inspection reports for 21 CFR 111 facilities, TGA GMP Clearance, EU GMP, Japan FFC or NSF/USP equivalent certification) or direct MFDS overseas inspection. Importer-of-record obligations include overseas manufacturer GMP equivalence demonstration, per-SKU import registration, MFDS labelling compliance verification, and post-market adverse reaction reporting. Significant MFDS GMP findings at the overseas facility — including non-compliance with the Korean importer's documented equivalence claim — can trigger import suspension for affected SKUs.
Labelling, post-market surveillance and the Korean consumer-facing discipline
Korean HFF labelling under the Health Functional Foods Act and MFDS labelling standards requires the distinctive HFF mark (건강기능식품 graphic mark with MFDS approval number), full Korean-language label content including functional ingredient name and content, function claim using MFDS-approved wording, recommended daily intake, recommended intake method and timing, suitable and unsuitable population statements, manufacturer/importer details, manufacturing date and shelf life, allergen declaration per Korean allergen list (which differs from US Big-9 in some elements, notably inclusion of buckwheat and exclusion of sesame), storage conditions, and warning statements specific to the functional ingredient. Post-market surveillance includes MFDS random and targeted sampling with public publication of any quality or labelling findings, adverse reaction reporting via the Korea Adverse Event Reporting System for Food, voluntary and mandatory recall procedures, and the periodic re-evaluation of Generic Functional Ingredient List entries as new evidence emerges.
More on labelling, post-market surveillance and the Korean consumer-facing discipline
The Korean consumer-facing discipline is rigorous — Korea's HFF market is one of the most label-literate consumer environments globally with mainstream media coverage of MFDS findings, social-media-driven consumer scrutiny of ingredient content and origin, and high sensitivity to imported product Korean-language label quality.
Questions
Can we sell our US-DSHEA supplement in Korea without MFDS HFF certification?
No — any product marketed in Korea with health-function claims requires HFF status under the Health Functional Foods Act. US DSHEA compliance does not substitute. Products without HFF certification cannot make function claims in Korea regardless of formulation or evidence. The pathways are Generic HFF (using ingredients on the MFDS Functional Ingredient List, typical 90-day review) or Individually-Approved HFF (novel ingredients, 6-18 month review with full safety and function dossier). Imported HFF requires Korean importer-of-record registration, per-SKU MFDS registration and overseas manufacturer GMP equivalence verification. The alternative is positioning the product as general food without function claims, which materially restricts marketing positioning.
What is the difference between Generic HFF and Individually-Approved HFF?
Generic HFF uses functional ingredients from the MFDS-published Functional Ingredient List with MFDS-specified daily dose ranges, function claims, conditions of use and standard analytical methods — open to any manufacturer meeting the requirements. Individually-Approved HFF covers novel functional ingredients outside the Generic List, requiring full MFDS scientific evidence review and granted to the specific applicant as a commercial protection mechanism. Generic is faster and lower-cost but restricted to the published ingredient scope. Individually-Approved enables differentiated product positioning with novel ingredients and approval-period commercial protection but requires substantial evidence investment and longer timeline. Many premium Korean brands operate hybrid portfolios with Generic HFF baseline and Individually-Approved hero ingredients.
Does our FDA-inspected 21 CFR 111 facility qualify for Korean HFF import?
Generally yes via MFDS overseas-manufacturer registration with documented GMP equivalence — FDA 21 CFR 111 inspection reports are typically accepted as evidence of GMP equivalent to MFDS HFF GMP standards. The Korean importer of record is responsible for compiling and maintaining the GMP equivalence demonstration and submitting per-SKU import registration to MFDS. Significant FDA inspection findings, Form 483 observations or Warning Letter at the overseas facility can cascade to MFDS import suspension for affected SKUs — proactive notification by the importer is the expected practice. Some 21 CFR 111 manufacturers add NSF GMP or USP Verified facility certification to strengthen the equivalence demonstration.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Food Processing Operations Guide
Safe changeovers. Right labels. Every lot traceable.
- The rules and the plan
- Supplier to filled tray
- Allergen changeovers and pack checks
- Trace, recall and record review
Plus Evidence map and four worksheets.
Get the food processing guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Food Processing Operations Guide
Safe changeovers. Right labels. Every lot traceable.
Keep reading
- China Health Food Readiness: Blue Hat Registration and CBEC
Pet Food and Animal Food cGMP Readiness: 21 CFR 507
BRCGS Food Safety Issue 9 Guide: Culture, HACCP, Traceability and Audits
Canada Natural Health Products Regulations: Licences, GMP, Labels and Reporting
Canada NNHPD: NPN, Monographs, Site Licence and Claims
EU 10/2011 Plastics Food Contact: Union List, Migration Limits and the Declaration of Compliance